286 related articles for article (PubMed ID: 17691952)
1. Zoledronic acid - a multiplicity of anti-cancer action.
Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid: multiplicity of use across the cancer continuum.
Lipton A
Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
[TBL] [Abstract][Full Text] [Related]
3. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
Li J; Rugo HS
Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid use in cancer patients: more than just supportive care?
Coleman R; Cook R; Hirsh V; Major P; Lipton A
Cancer; 2011 Jan; 117(1):11-23. PubMed ID: 21235033
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
Saad F; Mulders P
Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Sonnemann J; Bumbul B; Beck JF
Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
[TBL] [Abstract][Full Text] [Related]
8. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
9. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
12. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
Mitrofan LM; Pelkonen J; Mönkkönen J
Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
[TBL] [Abstract][Full Text] [Related]
13. Nitrogen-containing bisphosphonates and cancer immunotherapy.
Clézardin P; Massaia M
Curr Pharm Des; 2010; 16(27):3007-2014. PubMed ID: 20722623
[TBL] [Abstract][Full Text] [Related]
14. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Santini D; Vincenzi B; Hannon RA; Brown JE; Dicuonzo G; Angeletti S; La Cesa A; Coleman RE; Tonini G; Budillon A; Caraglia M; Holen I
Oncol Rep; 2006 May; 15(5):1351-7. PubMed ID: 16596210
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation.
Yamada J; Tsuno NH; Kitayama J; Tsuchiya T; Yoneyama S; Asakage M; Okaji Y; Shuno Y; Nishikawa T; Tanaka J; Takahashi K; Nagawa H
J Surg Res; 2009 Jan; 151(1):115-20. PubMed ID: 18619615
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
[TBL] [Abstract][Full Text] [Related]
18. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
Fanale D; Amodeo V; Bazan V; Insalaco L; Incorvaia L; Barraco N; Castiglia M; Rizzo S; Santini D; Giordano A; Castorina S; Russo A
Oncotarget; 2016 May; 7(20):29321-32. PubMed ID: 27081088
[TBL] [Abstract][Full Text] [Related]
19. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
Neville-Webbe Hl; Coleman RE
Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
[TBL] [Abstract][Full Text] [Related]
20. Additive effects of zoledronic acid and propranolol on bone density and biochemical markers of bone turnover in osteopenic ovariectomized rats.
Khajuria DK; Razdan R; Mahapatra DR
Rev Bras Reumatol; 2015; 55(2):103-12. PubMed ID: 25582996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]